<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        132-172-02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        AMOCLAN 228MG\5ML SUSP
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        AMOXICILLIN, CLAVULANIC ACID
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        40, 5.6
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for oral suspension
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        70
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        8.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Hikma Pharmaceuticals PLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Hikma Pharmaceuticals PLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Hikma Pharmaceuticals PLC
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01CR02
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Amoclan BID is an antibiotic and works by killing bacteria that cause infections. It contains two different medicines called amoxicillin and clavulanic acid. Amoxicillin belongs to &nbsp;a &nbsp;group &nbsp;of &nbsp;medicines &nbsp;called &nbsp;&ldquo;penicillins&rdquo; &nbsp;that &nbsp;can sometimes be stopped from working (made inactive). The other active component (clavulanic acid) stops this from happening.</p><p>Amoclan BID is used in babies and children to treat the following infections:</p><ul><li>Middle ear and sinus infections</li><li>Respiratory tract infections</li><li>Urinary tract infections</li><li>Skin&nbsp;and soft tissue&nbsp;infections including&nbsp;dental infections</li><li>Bone and joint infections.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not give your child Amoclan BID</strong></p><ul><li>If they are allergic to amoxicillin, clavulanic acid, penicillin, or any of the other ingredients of Amoclan BID (listed in section 6).</li><li>If they have ever had a severe allergic reaction to any other antibiotic. This can include a skin rash or swelling of the face or throat.</li><li>If &nbsp;you have ever had liver problems&nbsp;or jaundice (yellowing of the skin) when taking an antibiotic.</li></ul><p>Do not give Amoclan BID to your child if any of the above apply to your child. If you are not sure, talk to their doctor or pharmacist before giving Amoclan BID.</p><p><strong>Wa</strong><strong>r</strong><strong>n</strong><strong>i</strong><strong>n</strong><strong>g</strong><strong>s and Precautions</strong></p><p>Check with their doctor, pharmacist or nurse before giving your child Amoclan BID if they:</p><ul><li>Have glandular fever</li><li>Are being treated for liver or kidney problems</li><li>Are not passing water regularly.</li></ul><p>If you are not sure if any of the above apply to your child, talk to their doctor or pharmacist before giving Amoclan BID.</p><p>In some cases, your doctor may investigate the type of bacteria that is causing your child&rsquo;s infection. Depending on the results, your child may be given a different strength of Amoclan or a different medicine.</p><p><em>Conditions you need to look out for</em></p><p>Amoclan BID can make some existing conditions worse, or cause serious side effects. These include allergic reactions, &nbsp;convulsions &nbsp;(fits) &nbsp;and &nbsp;inflammation&nbsp; of &nbsp;the large intestine. You must look out for certain symptoms while your child is taking Amoclan BID, to reduce the risk of any problems. See &lsquo;Conditions you need to look out for&rsquo; in Section 4.</p><p><em>Blood and urine tests</em></p><p>If your child is having blood tests (such as red blood cell status tests or liver function tests) or urine tests (for glucose), let the doctor or nurse know that they are taking Amoclan BID. This is because Amoclan BID can affect the results of these types of tests.</p><p><strong>O</strong><strong>ther medicines and Amoclan BID</strong></p><p>Tell your doctor or pharmacist if your child is taking, has recently taken or might take any other medicines.</p><ul><li>If your child is taking allopurinol (used for gout) with Amoclan BID, it may be more likely that they will have an allergic skin reaction.</li><li>If your child is taking probenecid (used for gout), your doctor may decide to adjust your dose of Amoclan BID.</li><li>If medicines to help stop blood clots (such as warfarin) are taken with Amoclan BID then extra blood tests may be needed.</li><li>Amoclan BID can affect how methotrexate (a medicine used to treat cancer or rheumatic diseases) works.</li><li>Amoclan BID can affect how mycophenolate mofetil (a medicine used to prevent the rejection of transplanted organs) works.</li></ul><p><strong>Pregnancy and breast-feeding</strong></p><p>If your child who is about to take this medicine is pregnant or breast-feeding, thinks they may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>Amoclan BID can have side effects and the symptoms may make you unfit to drive. Do not drive or operate machinery unless you are feeling well.</p><p><strong>Amoclan BID contains aspartame</strong></p><p>Amoclan BID contains aspartame which is a source of phenylalanine. This may be harmful for children born with a condition called &rsquo;phenylketonuria&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always give Amoclan BID exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><em>Adults and children weighing 40 kg or over</em></p><p>This suspension is not usually recommended for adults and children weighing 40 kg and over. Ask your doctor or pharmacist for advice.</p><p><em>Children weighing less than 40 kg</em></p><p>All doses are worked out depending on the child&rsquo;s body weight in kilograms.</p><ul><li>Your doctor will advise you how much Amoclan BID you should give to your baby or child.</li><li>You may be provided with a plastic dosing syringe. Instructions on how to use the plastic dosing syringe are provided at the end of this leaflet. You should use this to give the correct dose to your baby or child.</li><li>Recommended dose &ndash; 25 mg/3.6 mg to 45 mg/6.4 mg for each kilogram of body weight a day, given in two divided doses.</li><li>Higher dose &ndash; up to 70 mg/10 mg for each kilogram of body weight a day, given in two divided doses.</li></ul><p><em>P</em><em>a</em><em>tients with kidney and liver problems</em></p><ul><li>If your child has kidney problems the dose might be lowered. A different strength or a different medicine may be chosen by your doctor.</li><li>If your child has liver problems, they may have more frequent blood tests to see how their liver is working.</li></ul><p><em>H</em><em>ow to give Amoclan BID</em></p><ul><li>Always shake the bottle well before each dose</li><li>Give with a meal</li><li>Space the doses evenly during the day, at least 4 hours apart. Do not take 2 doses in 1 hour.</li><li>Do not give your child Amoclan BID for more than 2 weeks. If your child still feels unwell they should go back to see the doctor.</li></ul><p><strong>I</strong><strong>f you give more Amoclan BID than you should</strong></p><p>If you give your child too much Amoclan BID, signs might include an upset stomach (feeling sick, being sick or diarrhoea) or convulsions. Talk to their doctor as soon as possible. Take the medicine bottle to show the doctor.</p><p><strong>I</strong><strong>f you forget to give Amoclan BID</strong></p><p>If you forget to give your child a dose, give it as soon as you remember. You should not give your child the next dose too soon, but wait about 4 hours before giving the next dose.</p><p>Do not give a double dose to make up for a forgotten dose.</p><p><strong>I</strong><strong>f your child stops taking Amoclan BID</strong></p><p>Keep giving your child Amoclan BID until the treatment is finished, even if they feel better.</p><p>Your child needs every dose to help fight the infection. If some bacteria survive they can cause the infection to come back.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p><strong>Amoclan BID contains aspartame and golden syrup </strong></p><p>Aspartame is&nbsp;source &nbsp;of &nbsp;phenylalanine. &nbsp;It &nbsp;may &nbsp;be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.</p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The side effects below may happen with this medicine.</p><p>Conditions you need to look out for</p><p><strong>Allergic reactions:</strong></p><ul><li>Skin rash</li><li>Inflammation of blood vessels (vasculitis) which may be visible as red or purple raised spots on the skin, but can affect other parts of the body</li><li>Fever, joint pain, swollen glands in the neck, armpit or groin</li><li>Swelling,&nbsp;sometimes&nbsp;&nbsp;of&nbsp;the&nbsp;face&nbsp;or&nbsp;throat (angioedema), causing difficulty in breathing</li><li>Collapse</li></ul><p>Contact a doctor immediately if your child gets any of these symptoms. Stop taking Amoclan BID.</p><p><strong>I</strong><strong>n</strong><strong>flammation of large intestine</strong></p><p>Inflammation of the large intestine, causing watery diarrhoea usually with blood and mucus, stomach pain and/or fever.</p><p>Contact your doctor as soon as possible for advice if your child gets these symptoms.</p><p><strong>Ver</strong><strong>y common side effects</strong></p><p>These may affect more than 1 in 10 people:</p><ul><li>Diarrhoea (in adults).</li></ul><p><strong>C</strong><strong>o</strong><strong>mmon side effects</strong></p><p>These may affect up to 1 in 10 people:</p><ul><li>Thrush &nbsp;(candida &nbsp;- &nbsp;a yeast &nbsp;infection &nbsp;of &nbsp;the &nbsp;vagina, mouth or skin folds)</li><li>Feeling &nbsp;sick &nbsp;(nausea), &nbsp;especially &nbsp;when &nbsp;taking &nbsp;high doses. If affected give Amoclan BID with a meal</li><li>Vomiting</li><li>Diarrhoea (in children).</li></ul><p><strong>Uncommon side effects</strong></p><p>These may affect up to 1 in 100 people):</p><ul><li>Skin rash, itching</li><li>Raised itchy rash (hives)</li><li>Indigestion</li><li>Dizziness</li><li>Headache.</li></ul><p>Uncommon side effects that may show up in blood tests:</p><ul><li>Increase in some substances (enzymes) produced by the liver.</li></ul><p><strong>Rare side effects</strong></p><p>These may affect up to 1 in 1000 people:</p><ul><li>Skin rash, which may blister, and looks like small targets (central dark spots surrounded by a paler area, with a dark ring around the edge &ndash; erythema multiforme).</li></ul><p>If you notice any of these symptoms contact a doctor urgently.</p><p>Rare side effects that may show up in blood tests:</p><ul><li>Low number of cells involved in blood clotting</li><li>Low number of white blood cells</li></ul><p><strong>Frequency not known</strong></p><p>Frequency cannot be estimated from the available data.</p><ul><li>Allergic reactions (see above)</li><li>Inflammation of the large intestine (see above)</li><li>Inflammation&nbsp;&nbsp;of&nbsp;&nbsp;the&nbsp;&nbsp;protective membrane surrounding the brain (aseptic meningitis)</li><li>Serious skin reactions:</li></ul><p>₋ &nbsp;A widespread rash with blisters and peeling skin, particularly around the mouth, nose, eyes and genitals (Stevens-Johnson syndrome), and a more severe form, causing extensive peeling of the skin (more than 30% of the body surface-toxic epidermal necrolysis).</p><p>₋ &nbsp;Widespread red skin rash with small pus-containing blisters (bullous exfoliative dermatitis).</p><p>₋ &nbsp;A red, scaly rash with bumps under the skin and blisters (exanthemous pustulosis).</p><p>₋ &nbsp;Flu-like &nbsp;symptoms &nbsp;with &nbsp;a &nbsp;rash, &nbsp;fever, &nbsp;swollen glands, and abnormal blood test results (including increased white blood cells (eosinophilia) and liver enzymes) (Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)).</p><p>Contact a doctor immediately if your child gets any of these symptoms.</p><ul><li>Inflammation of the liver (hepatitis)</li><li>Jaundice, caused by increases in the blood of bilirubin (a substance produced in the liver) which may make your child&rsquo;s skin and whites of the eyes appear yellow</li><li>Inflammation of tubes in the kidney</li><li>Blood takes longer to clot</li><li>Hyperactivity</li><li>Convulsions&nbsp;(in&nbsp;people&nbsp;taking&nbsp;high&nbsp;doses&nbsp; of amoxicillin/clavulanic acid or who have kidney problems)</li><li>Black tongue which looks hairy</li><li>Stained &nbsp;teeth &nbsp;(in &nbsp;children), &nbsp;usually &nbsp;removed &nbsp;by brushing.</li></ul><p>Side effects that may show up in blood or urine tests:</p><ul><li>Severe reduction in the number of white blood cells</li><li>Low number of red blood cells (haemolytic anaemia)</li><li>Crystals in urine.</li></ul>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p><strong>Dry powder</strong>:</p><p>Store below 25&deg;C.</p><p>Store in the original carton to protect from moisture.</p><p><strong>Liquid suspension:</strong></p><p>Store in a refrigerator (2-8&deg;C).</p><p>Do not freeze.</p><p>Once made up, the suspension should be used within 7 days.</p><p>Do not use this medicine after the expiry date which is stated on the carton after Exp. Date. The expiry date refers to the last day of that month.</p><p>Do not use this medicine if you notice any visible signs of deterioration.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active ingredients are amoxicillin and clavulanic acid.</p><p>Each 5 ml of Amoclan BID 228 mg/5 ml Powder for Oral Suspension contains amoxicillin trihydrate equivalent to&nbsp;200 mg amoxicillin and potassium clavulanate equivalent to 28.5 mg clavulanic acid.</p><p>Each 5 ml of Amoclan BID 457 mg/5 ml Powder for Oral Suspension contains amoxicillin trihydrate equivalent to 400 mg amoxicillin and potassium clavulanate equivalent to 57 mg clavulanic acid.</p><p>The other ingredients are xanthan gum, aspartame, colloidal silicon dioxide, succinic acid, hydroxylpropyl methyl cellulose, orange flavor, golden syrup and silicon dioxide.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Amoclan BID 228 mg/5 ml Powder for Oral Suspension is white   to   off-white   powder   with   fruity   flavor   in aluminum-sealed type (III) amber glass bottles with a mark at 100 ml with child resistant caps with a plastic dosing syringe calibrated in milliliters (ml).
After  reconstitution,  it  is an off-white  to  pale yellow homogenous suspension with fruity flavor.
Pack size: 1 bottle (35 ml or 70 ml).
Not all pack sizes may be marketed.
Amoclan BID 457 mg/5 ml Powder for Oral Suspension is white   to   off-white   powder   with   fruity   flavor   in aluminum-sealed type (III) amber glass bottles with a mark at 100 ml with child resistant caps with a plastic dosing syringe calibrated in milliliters (ml).
After  reconstitution,  it  is an off-white  to  pale yellow homogenous suspension with fruity flavor.
Pack size: 1 bottle (70 ml).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Ma</strong><strong>r</strong><strong>keting Authorization Holder</strong></p><p>Hikma Pharmaceuticals</p><p>Bayader Wadi El Seer</p><p>Industrial Area</p><p>P.O Box 182400</p><p>Amman 11118, Jordan</p><p>Tel: (962-6)5802900</p><p>Fax: (962-6)5817102</p><p><strong>Manu</strong><strong>facturer</strong></p><p>Hikma Pharmaceuticals</p><p>Bayader Wadi El Seer</p><p>Industrial Area</p><p>P.O Box 182400</p><p>Amman 11118, Jordan</p><p>Tel: (962-6)5802900</p><p>Fax: (962-6)5817102</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 11/2018; version number SA2.5.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p style="direction: rtl;">أموكلان بي أي دي هو مضاد حيوي يعمل على قتل البكتيريا التي تسبب&nbsp;العدوى. ويحتوي على نوعين مختلفين من الأدوية هما أموكسيسيلين وحمض الكلافولانيك. وينتمي الأموكسيسيلين إلى مجموعة من الأدوية تُسمى &quot;البنسلينات&quot; التي يمكن أن يتم إيقاف مفعولها في بعض الأحيان (جعلها غير نشطة). المادة الفعالة الأخرى (حمض الكلافولانيك) تمنع حدوث ذلك.</p><p style="direction: rtl;">يُستخدم أموكلان بي أي دي للرضع والأطفال لعلاج الأنواع التالية من العدوى:</p><ul><li style="direction: rtl;">عدوى الأذن الوسطى و الجيوب الأنفية</li><li style="direction: rtl;">عدوى المسالك التنفسية</li><li style="direction: rtl;">عدوى المسالك البولية</li><li style="direction: rtl;">عدوى الجلد و الأنسجة الرخوة و التي من ضمنها العدوى السنِّية</li><li style="direction: rtl;">عدوى العظام و المفاصل</li></ul><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;"><strong>موانع إعطاء أموكلان بي أي دي لطفلك</strong></p><ul><li style="direction: rtl;">إذا كان طفلك يعاني من حساسية لأموكسيسيلين، حمض الكلافولانيك،&nbsp;البينيسيلين، أو لأي من المواد الأخرى المستخدمة في أموكلان بي أي&nbsp;دي (المدرجة في القسم 6).</li><li style="direction: rtl;">إذا سبق له أن عانى من رد فعل تحسسي شديد تجاه أي مضاد حيوي آخر، حيث يمكن أن يشمل ذلك الطفح الجلدي أو تورم الوجه أو الحنجرة.</li><li style="direction: rtl;">إذا سبق له أن عانى من مشكلات في الكبد أو من اليرقان (اصفرار الجلد) عند تناوله مضاد حيوي.</li></ul><p style="direction: rtl;">لا تعطي أموكلان بي أي دي لطفلك إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليه. استشر طبيبه أو الصيدلي قبل إعطاؤه أموكلان بي أي دي إذا لم تكن متأكدًا.</p><p style="direction: rtl;"><strong>الاحتياطات والتحذيرات</strong></p><p style="direction: rtl;">تحدث مع طبيب طفلك، الصيدلي أو الممرض قبل أموكلان بي أي دي إذا:</p><ul><li style="direction: rtl;">&nbsp;كان يعاني من حُمى غدّية.</li><li style="direction: rtl;">كان يخضع لعلاج مشاكل في الكبد أو الكلى.</li><li style="direction: rtl;">كان لا يتبول بانتظام.</li></ul><p style="direction: rtl;">استشر طبيبه أو الصيدلي قبل إعطاءه أموكلان بي أي دي إذا لم تكن متأكدًا من أن أ ي مما ذُكِّر أعلاه ينطبق عليه.</p><p style="direction: rtl;">في بعض الحالات، قد يتحرى الطبيب عن نوع البكتيريا التي تسبب لطفلك العدوى. ووفقًا للنتائج، قد يتم إعطاؤه أموكلان بتركيز مختلف أو يتم إعطاؤه دواءً مختلفًا.</p><p style="direction: rtl;"><em>الحالات التي ينبغي الانتباه إليها</em></p><p style="direction: rtl;">يمكن أن يزيد أموكلان بي أي دي بعض الحالات الموجودة سوءًا أو أن يتسبب في حدوث آثار جانبية خطيرة. والتي تشمل ردود الأفعال التحسسية، الاختلاجات (النوبات)، والعدوى في الأمعاء الغليظة. يجب عليك الانتباه لظهور أعراض معينة أثناء تناول طفلك أموكلان بي أي دي، للحد من خطورة أي مشكلات. انظر &quot;الحالات التي ينبغي الانتباه إليها&quot; في القسم 4.</p><p style="direction: rtl;"><em>اختبارات الدم والبول</em></p><p style="direction: rtl;">أخبر الطبيب أو الممرضة بأن طفلك يتناول أموكلان بي أي دي إذا كانت ستجرى له اختبارات دم (مثل اختبارات تقييم وضع خلايا الدم الحمراء أو اختبارات وظائف الكبد) أو اختبارات بول (لفحص الجلوكوز). و ذلك لأن أموكلان بي أي دي قد يؤثر على نتائج هذه الاختبارات.</p><p style="direction: rtl;"><strong><strong>الأدوية الأخرى و أموكلان بي أي دي</strong></strong></p><p style="direction: rtl;">يُرجى إبلاغ الطبيب أو الصيدلي إذا كان طفلك يتناول، تناول مؤخر ا أو من الممكن أن يتناول أية أدوية أخرى.</p><ul><li style="direction: rtl;">&nbsp;إذا كان طفلك يتناول ألوبيرينول (يُستخدم لعلاج النقرس) مع أموكلان بي أي دي، فإن احتمالية أن يصاب برد فعل تحسسي في الجلد تكون أكبر.</li><li style="direction: rtl;">إذا كان يتناول بروبينيسيد (يُستخدم لعلاج النقرس)، فقد يقرر طبيبه تعديل جرعة أموكلان بي أي دي.</li><li style="direction: rtl;">إذا كان طفلك يأخذ أدوية تساعد على إيقاف جلطات الدم (مثل الوارفارين) مع أموكلان بي أي دي، فقد يلزمه إجراء اختبارات دم إضافية.</li><li style="direction: rtl;">يمكن أن يؤثر أموكلان بي أي دي على مفعول ميثوتريكسات (دواء يُستخدم لعلاج السرطان أو الأمراض الروماتيزمية).</li><li style="direction: rtl;">قد يؤثر أموكلان بي أي دي على مفعول ميكوفينولات موفيتيل (دواء يُستخدم لمنع رفض الجسم للأعضاء المزروعة).</li></ul><p style="direction: rtl;"><strong>الحمل والرضاعة</strong></p><p style="direction: rtl;">إذا كانت طفلتك التي ستتناول هذا الدواء حاملا أو مرضع، تعتقد بأنها حاملا أو تخطط لذلك فيرجى استشارة الطبيب أو الصيدلي قبل تناولها لهذا الدواء.</p><p style="direction: rtl;"><strong><strong>تأثير أموكلان </strong>بي أي دي</strong><strong><strong> القيادة واستخدام الآلات</strong></strong></p><p style="direction: rtl;">يمكن أن يسبب أموكلان بي أي دي آثاراً جانبية وقد تجعلك الأعراض غير مؤهل للقيادة. تجنب القيادة أو تشغيل الآلات إلا إذا شعرت أنك بحالة جيدة.</p><p style="direction: rtl;"><strong><strong>يحتوي أموكلان بي أي دي على الأسبارتام</strong></strong></p><p style="direction: rtl;">يحتوي أموكلان بي أي دي على الأسبارتام والذي يعد أحد مصادر الفينيل ألانين. قد يكون هذا مضراً للأطفال الذين شخصوا عند الولادة بحالة مرضية تسمى &quot;بيلة الفينيل كيتون&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">ينبغي عليك إعطاء أموكلان بي أي دي دائمًا وفقًا لتعليمات الطبيب أو الصيدلي. استشر الطبيب أو الصيدلي إذا لم تكن متأكدًا.</p><p style="direction: rtl;"><em>البالغون والأطفال بوزن 40 كلغم فما فوق</em></p><p style="direction: rtl;">لا يوصى عادة باستخدام هذا المعلق للبالغين والأطفال بوزن 40 كلغم فما&nbsp;فوق. قم باستشارة الطبيب أو الصيدلي.</p><p style="direction: rtl;"><em>الأطفال بوزن أقل من 40 كلغم</em></p><p style="direction: rtl;">يتم حساب جميع الجرعات بناءً على وزن جسم الطفل بالكيلوجرام.</p><ul><li style="direction: rtl;">سيصف لك الطبيب جرعة أموكلان بي أي دي التي ينبغي أن تعطيها لرضيعك أو طفلك.</li><li style="direction: rtl;">قد يتم تزويدك بمحقنة قياس بحيث تستخدمها لإعطاء الجرعة الصحيحة&nbsp;لرضيعك أو طفلك. تعليمات طريقة استخدام المحقنة مزودة في نهاية&nbsp;هذه النشرة.</li><li style="direction: rtl;">الجرعة الموصى بها هي 25 ملغم/ 3.6 ملغم إلى 45 ملغم/ 6.4 ملغم لكل كيلوغرام من وزن الجسم يوميا مقسمة على جرعتين.</li><li style="direction: rtl;">الجرعة الأعلى قد تصل إلى 70 ملغم/ 10 ملغم لكل كيلوغرام يوميا مقسمة على جرعتين.</li></ul><p style="direction: rtl;"><em>المرضى الذين يعانون من مشكلات في الكلى والكبد</em></p><ul><li style="direction: rtl;">قد يتم تخفيض الجرعة إذا كان طفلك يعاني من مشكلات في الكلى. فقد يختار له طبيبه تركيزًا مختلفًا من الدواء أو يختار له دواءً مختلفًا.</li><li style="direction: rtl;">قد يحتاج لإجراء اختبارات دم بشكل متكرر أكثر للتأكد من أن الكبد يعمل إذا كان يعاني من مشكلات في الكبد.</li></ul><p style="direction: rtl;"><em>كيفية إعطاء أموكلان بي أي دي</em></p><ul><li style="direction: rtl;">قم برج القارورة جيدًا قبل كل جرعة</li><li style="direction: rtl;">قم بإعطاء الجرعة عند تناول الوجبة الطعام.</li><li style="direction: rtl;">وزع الجرعات بشكل متساوٍ أثناء اليوم بفاصل 4 ساعات على الأقل بين&nbsp;كل منها. لا تقم بإعطاء جرعت ين خلال ساعة واحدة.</li><li style="direction: rtl;">لا&nbsp;تقم بإعطاء طفلك أموكلان بي أي دي لأكثر من أسبوعين. يجب عليك مراجعة الطبيب إذا كان طفلك لا يزال يشعر بالتوعك.</li></ul><p style="direction: rtl;"><strong>إذا أعطيت جرعة زائدة من&nbsp;أموكلان بي أي دي</strong></p><p style="direction: rtl;">إذا أعطيت أموكلان بي أي دي لطفلك بجرعة أكبر مما ينبغي، فقد تظهر لديه علامات تشمل اضطراب المعدة (الغثيان، التقيؤ أو الإسهال) أو الاختلاجات. تحدث إلى طبيبه بأسرع وقت ممكن. وأحضر العبوة الخارجية أو الداخلية للدواء لعرضها على طبيبه.</p><p style="direction: rtl;"><strong><strong>إذا نسيت إعطاء&nbsp;</strong>أموكلان بي أي دي</strong></p><p style="direction: rtl;">في حال نسيت إعطاء الجرعة لطفلك، أعطها له فور تذكرها. يجب ألا تعطي الجرعة التالية خلال وقت قصير من إعطاؤك الجرعة المنسية، ولكن انتظر قرابة 4 ساعات قبل إعطاء الجرعة التالية.</p><p style="direction: rtl;">لا تقم بإعطاء جرعة مضاعفة من أجل تعويض الجرعة المنسية.</p><p style="direction: rtl;"><strong><strong>إذا توقفت عن إعطاء</strong> أموكلان بي أي دي</strong></p><p style="direction: rtl;">استمر في إعطاء أموكلان بي أي دي لطفلك حتى ينتهي العلاج المقرر له حتى إذا شعر بتحسن.</p><p style="direction: rtl;">فهو بحاجة إلى كل جرعة لمحاربة العدوى. إذا تمكنت بعض البكتيريا من البقاء حية، فيمكنها أن تتسبب في ظهور العدوى مرة أخرى.</p><p style="direction: rtl;">يرجى استشارة الطبيب، الصيدلي أو الممرض إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء.</p><p style="direction: rtl;"><strong><strong>يحتوي أموكلان بي أي دي على الأسيارتام و شراب جولدن</strong></strong></p><p style="direction: rtl;">أسبارتام مصدره الفينيل ألانين. قد يكون مضراُ إذا كان لديك فينيل كيتويوريا، اضطراب جيني نادر حيث يحدث تراكم للفينيل ألانين لأن الجسم لا يستطيع التخلص من بشكل مناسب.</p><p style="direction: rtl;">تحدث إلى طبيبك قبل تناول هذا المستحضر الدوائي، إذا أخبرك طبيبك أن لديك عدم تحمل لبعض أنواع السكريات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">مثل جميع الأدوية، قد يسبب هذا الدواء آثاراً جانبيةً، إلا أنه ليس بالضرورة&nbsp;أن تحدث لدى جميع مستخدمي هذا الدواء. يمكن للأعراض الجانبية أدناه&nbsp;أن تحدث مع هذا الدواء.</p><p style="direction: rtl;">الحالات التي ينبغي الانتباه إليها:</p><p style="direction: rtl;"><strong>ردود الفعل التحسسية:</strong></p><ul><li style="direction: rtl;">طفح جلدي.</li><li style="direction: rtl;">التهاب الأوعية الدموية (التهاب وعائي) الذي قد يظهر على هيئة بقع حمراء أو أرجوانية ناتئة على الجلد، إلا أنه يمكن أن يصيب أجزاء أخرى من الجسم.</li><li style="direction: rtl;">الحمى، ألم المفاصل، تورم الغدد في الرقبة، الإبط أو الأُربيَّة.</li><li style="direction: rtl;">تورم، أحيانًا في الوجه أو الحنجرة (الوذمة الوعائية)، مما يسبب صعوبة في التنفس.</li><li style="direction: rtl;">هبوط وعائي.</li></ul><p style="direction: rtl;">اتصل بالطبيب على الفور إذا ظهرت على طفلك أي من هذه الأعراض وتوقف عن إعطاءه أموكلان بي أي دي.</p><p style="direction: rtl;"><strong>عدوى في الأمعاء الغليظة</strong></p><p style="direction: rtl;">عدوى في الأمعاء الغليظة مما يسبب إسهالا مائيًّا ويكون عادة مصحوبًا بوجود دم ومخاط، ألم في المعدة و/أو حمى.</p><p style="direction: rtl;">اتصل بالطبيب في أقرب وقت ممكن إذا ظهرت على طفلك هذه الأعراض.</p><p style="direction: rtl;"><strong><strong>آثار جانبية شائعة جدًا</strong></strong></p><p style="direction: rtl;">قد تؤثر على أكثر من شخص من كل 10 أشخاص</p><ul><li style="direction: rtl;">الإسهال (لدى البالغين).</li></ul><p style="direction: rtl;"><strong>آثار جانبية شائعة</strong></p><p style="direction: rtl;">قد تؤثر على ما يصل إلى شخص من كل 10 أشخاص</p><ul><li style="direction: rtl;">السُلاق&nbsp;(المُبْيَضَّة&nbsp;- عدوى فطرية تصيب المهبل، الفم أو طيّات الجلد).</li><li style="direction: rtl;">الغثيان، خاصة عند تناول جرعات كبيرة. يجب إعطاء أموكلان بي أي دي مع وجبة الطعام في حال تعرض طفلك لذلك.</li><li style="direction: rtl;">القيء.</li><li style="direction: rtl;">الإسهال (لدى الأطفال).</li></ul><p style="direction: rtl;"><strong>آثار جانبية غير شائعة</strong></p><p style="direction: rtl;">قد تؤثر على ما يصل إلى شخص من كل 100 شخص</p><ul><li style="direction: rtl;">طفح جلدي، حكة.</li><li style="direction: rtl;">طفح جلدي مثير للحكة ناتئ عن سطح الجلد (الشرى).</li><li style="direction: rtl;">عسر الهضم.</li><li style="direction: rtl;">الدوخة.</li><li style="direction: rtl;">الصداع.</li></ul><p style="direction: rtl;">آثار جانبية غير شائعة قد تظهر في اختبارات الدم:</p><ul><li style="direction: rtl;">زيادة في إفراز بعض المواد (الإنزيمات) التي ينتجها الكبد.</li></ul><p style="direction: rtl;"><strong>آثار جانبية نادرة</strong></p><p style="direction: rtl;">قد تؤثر على ما يصل إلى شخص من كل 1000 شخص</p><ul><li style="direction: rtl;">طفح جلدي قد يصاحبه نفطات، ويبدو على هيئة أهداف صغيرة (بقع داكنة المركز تحيط بها منطقة شاحبة و يحفها حلقة داكنة - حمامي عديدة&nbsp;الأشكال).</li></ul><p style="direction: rtl;">اتصل بالطبيب بشكل عاجل إذا لاحظت ظهور أي من هذه الأعراض.</p><p style="direction: rtl;">آثار جانبية نادرة قد تظهر في اختبارات الدم:</p><ul><li style="direction: rtl;">انخفاض عدد الخلايا المشاركة في عملية تجلط الدم.</li><li style="direction: rtl;">انخفاض عدد خلايا الدم البيضاء.</li></ul><p style="direction: rtl;"><strong>آثار جانبية لا يمكن معرفة تكرارها</strong></p><p style="direction: rtl;">قد تحدث آثار جانبية لا يمكن تقدير تكرارها من خلال البيانات المتاحة.</p><ul><li style="direction: rtl;">ردود فعل تحسسية (انظر أعلاه).</li><li style="direction: rtl;">عدوى في الأمعاء الغليظة (انظر أعلاه).</li><li style="direction: rtl;">عدوى في الغشاء الحافظ المحيط للدماغ (الْتِهابُ السَّحايا الحادُّ العَقيم).</li><li style="direction: rtl;">ردود فعل خطيرة في الجلد:</li></ul><p style="direction: rtl;">- طفح جلدي منتشر بشكل واسع مع وجود نفطات وتقشر في الجلد، خاصة حول الفم، الأنف، العينين، والأعضاء التناسلية (متلازمة ستيفن جونسون)، وحدوث شكل أكثر شدة منه يسبب تقشر جلد كثيف (أكثر من 30 % من سطح الجسم - تقشر الأنسجة المتموتة البشروية التسممي).</p><p style="direction: rtl;">- طفح جلدي أحمر اللون منتشر بشكل واسع مع وجود نفطات صغيرة تحتوي على قيح (جلاّد فقاعي تقشري).</p><p style="direction: rtl;">- طفح جلدي متقشر أحمر اللون، مع وجود تحاديب أسفل الجلد و نفطات (بثور طفحية).</p><p style="direction: rtl;">- أعراض مشابهة للانْفلوَنْزَا مصحوبة بالطفح الجلدي، الحمّى، تورم الغدد ونتائج غير طبيعيّة&nbsp;لفحص الدم (تتضمّن زيادة&nbsp;في عدد خلايا الدّم البيضاء (اليُوزينِّيَّات) وأنزيمات الكبد) (التفاعل الدوائي مع اليُوزينِّيَّات والأعراض الجهازية).</p><p style="direction: rtl;">اتصل بالطبيب على الفور إذا ظهرت على طفلك أي من هذه الأعراض.</p><ul><li style="direction: rtl;">التهاب الكبد.</li><li style="direction: rtl;">اليرقان الذي يسببه زيادة مستوى مادة بيليروبين في الدم (مادة تُنتج في الكبد) التي قد تجعل الجلد وبياض العينين يبدو أصفر.</li><li style="direction: rtl;">التهاب القنوات في الكلى.</li><li style="direction: rtl;">استغراق الدم فترة طويلة كي يتجلط.</li><li style="direction: rtl;">فرط النشاط.</li><li style="direction: rtl;">الاختلاجات (في الأشخاص الذين يأخذون جرعات عالية من أموكسيسيلين/حمض الكلافولانيك أو الذين يعانون من مشكلات في الكلى).</li><li style="direction: rtl;">لسان أسود اللون مما يجعله يبدو وكأنه مشعرًا.</li><li style="direction: rtl;">تصبغات في الأسنان (لدى الأطفال) عادة ما يتم التخلص منها عن طريق تفريش الأسنان.</li></ul><p style="direction: rtl;">آثار جانبية قد تظهر في اختبارات الدم أو البول:</p><ul><li style="direction: rtl;">انخفاض شديد في عدد خلايا الدم البيضاء.</li><li style="direction: rtl;">انخفاض عدد خلايا الدم الحمراء (فقر الدم الانحلالي).</li><li style="direction: rtl;">وجود بلورات في البول.</li></ul><p style="direction: rtl;">أخبر الطبيب، مقدم الرعاية الصحية، أو الصيدلي إذا أصبح أي من الآثار الجانبية خطيراً أو إذا لاحظت ظهور آثار جانبية غير مذكورة بالنشرة.</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">احفظ هذا الدواء بعيد اً عن مرأى ومتناول الأطفال.</p><p style="direction: rtl;"><strong>المسحوق الجاف:</strong></p><p style="direction: rtl;">يحفظ عند درجة حرارة أقل من &nbsp;ᵒ25&nbsp;مئوية.</p><p style="direction: rtl;">يحفظ في العبوة الأصلية لحمايته من الرطوبة.</p><p style="direction: rtl;"><strong>المعلّق اًلمحضر:</strong></p><p style="direction: rtl;">يحفظ بالثلاجة (2-​&nbsp;ᵒ8 مئوية).</p><p style="direction: rtl;">لا يحفظ مجمداً.</p><p style="direction: rtl;">يجب استخدام المعلق المحضر خلال 7 أيام من تحضيره.</p><p style="direction: rtl;">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة الخارجية. يشير تاريخ الانتهاء إلى اليوم الأخير من ذلك الشهر.</p><p style="direction: rtl;">لا تستخدم هذا الدواء إذا لاحظت علامات تلف واضحة عليه.</p><p style="direction: rtl;">لا تتخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية.</p><p style="direction: rtl;">اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. اتبع هذه الإجراءات للحفاظ على سلامة البيئة.</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p style="direction: rtl;">المواد الفعالة هي أموكسيسيلين وحمض الكلافولانيك.</p><p style="direction: rtl;">يحتوي كل 5 مللتر من أموكلان بي أي دي 228 ملغم/ 5 مللتر مسحوق لتشكيل المعلق الفموي على أموكسيسيلين ثلاثي الهيدرات بما يعادل 200 ملغم من الأموكسيسيلين، وعلى كلافولانات البوتاسيوم بما يعادل 28.5 ملغم من حمض الكلافولانيك.</p><p style="direction: rtl;">يحتوي كل 5 مللتر من أموكلان بي أي دي 457 ملغم/ 5 مللتر مسحوق لتشكيل المعلق الفموي على أموكسيسيلين ثلاثي الهيدرات بما يعادل 400 ملغم من الأموكسيسيلين، وعلى كلافولانات البوتاسيوم بما يعادل 57 ملغم من حمض الكلافولانيك.</p><p style="direction: rtl;">المواد الأخرى هي صمغ الزانثان، أسبارتام، ثاني أكسيد السيليكون الغروي، حمض السكسينسك، هيدروكسي بروبيل ميثيل السيليولوز، مسحوق نكهة البرتقال، شراب جولدن وثنائي أكسيد السيليكون.</p><p style="direction: rtl;">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            أموكلان بي أي دي 228 ملغم/ 5 مللتر مسحوق لتشكيل المعلق الفموي هو مسحوق أبيض حليبي بنكهة الفواكه ويأتي في قوارير زجاجية كهرمانية اللون من النوع (lll)، مغلقة بختم الألمنيوم، مع علامة دالّة عند 100 مللتر ومغطاة بأغطية مقاومة لعبث الأطفال مع محقنة قياس الجرعات مدرجة بالمللتر (مل).
بعد الحلّ،  هو معلّق متجانس لونه أبيض فاهي يميل إلى الأصفر الشاحب بطعم الفواكه.
حجم العبوة: عبوة واحدة (بحجم 35 مللتر أو 70 مللتر).
من الممكن ألا يتم تسويق جميع أحجام العبوات.
أموكلان بي أي دي 457 ملغم/ 5 مللتر مسحوق لتشكيل المعلق الفموي هو مسحوق أبيض حليبي بنكهة الفواكه ويأتي في في قوارير زجاجية كهرمانية اللون من النوع (lll)، مغلقة بختم الألمنيوم، مع علامة دالّة عند 100 مللتر ، ومغطاة بأغطية مقاومة لعبث الأطفال مع محقنة قياس الجرعات مدرجة بالمللتر (مل).
بعد الحلّ، هو معلّق متجانس لونه أبيض فاهي يميل إلى الأصفر الشاحب بطعم الفواكه.
حجم العبوة: عبوة واحدة (بحجم 70 مللتر).
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><div style="direction: rtl;"><strong style="text-align:unset">اسم وعنوان مالك رخصة التسويق</strong></div><div style="direction: rtl;"><span style="text-align:unset">شركة أدوية الحكمة</span></div><div style="direction: rtl;"><span style="text-align:unset">بيادر وادي السير- المنطقة الصناعية</span></div><div style="direction: rtl;"><span style="text-align:unset">صندوق بريد 182400</span></div><div style="direction: rtl;"><span style="text-align:unset">عمان 11118</span></div><div style="direction: rtl;"><span style="text-align:unset">الأردن</span></div><div style="direction: rtl;"><span style="text-align:unset">هاتف: 96265802900</span>+</div><div style="direction: rtl;"><span style="text-align:unset">فاكس: 96265817102</span>+</div><div style="direction: rtl;"><strong><strong style="text-align:unset">الشركة المصنعة</strong></strong></div><div style="direction: rtl;"><span style="text-align:unset">شركة أدوية الحكمة</span></div><div style="direction: rtl;"><span style="text-align:unset">بيادر وادي السير- المنطقة الصناعية</span></div><div style="direction: rtl;"><span style="text-align:unset">صندوق بريد 182400</span></div><div style="direction: rtl;"><span style="text-align:unset">عمان 11118</span></div><div style="direction: rtl;"><span style="text-align:unset">الأردن</span></div><div style="direction: rtl;"><span style="text-align:unset">هاتف: 96265802900</span>+</div><div style="direction: rtl;"><span style="text-align:unset">فاكس: 96265817102</span>+</div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            / تمت مراجعة هذه النشرة بتاريخ 2018/11 ، رقم النسخة: SA2.4.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Amoclan BID 228 mg/5 ml Powder for Oral Suspension
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each 5 ml of Amoclan BID 228 mg/5 ml suspension contains amoxicillin trihydrate equivalent to 200 mg amoxicillin and potassium clavulanate equivalent to 28.5 mg clavulanic acid.

Excipients with known effect: aspartame and golden syrup.

For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Powder for oral suspension.

White to off-white powder with fruity flavor.

After reconstitution, it is an off-white to pale yellow homogenous suspension with fruity flavor.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Amoclan BID is indicated for the treatment of the following infections in adults and children (see sections 4.2, 4.4 and 5.1):</p><ul><li>Acute bacterial sinusitis (adequately diagnosed)</li><li>Acute otitis media</li><li>Acute exacerbations of chronic bronchitis (adequately diagnosed)</li><li>Community acquired pneumonia</li><li>Cystitis</li><li>Pyelonephritis</li><li>Skin and soft tissue infections in particular cellulitis, animal bites, severe dental abscess with spreading cellulitis.</li><li>Bone and joint infections, in particular osteomyelitis.</li></ul><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Po</u><u>s</u><u>o</u><u>l</u><u>o</u><u>g</u><u>y</u></p><p>Doses are expressed throughout in terms of amoxicillin/clavulanic acid content except when doses are stated in terms of an individual component.</p><p>&nbsp;</p><p>The dose of Amoclan BID that is selected to treat an individual infection should take into account:</p><ul><li>The expected pathogens and their likely susceptibility to antibacterial agents (see section 4.4)</li><li>The severity and the site of the infection</li><li>The age, weight and renal function of the patient as shown below.</li></ul><p>&nbsp;</p><p>The use of alternative presentations of Amoclan BID (e.g. those that provide higher doses of amoxicillin and/or different ratios of amoxicillin to clavulanic acid) should be considered as necessary (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>For children &lt; 40 kg, this formulation of Amoclan BID provides a maximum daily dose of 1000- 2800 mg amoxicillin/143-400 mg clavulanic acid, when administered as recommended below. If it is considered that a higher daily dose of amoxicillin is required, it is recommended that another preparation of Amoclan BID is selected in order to avoid administration of unnecessarily high daily doses of clavulanic acid (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>The duration of therapy should be determined by the response of the patient. Some infections (e.g. osteomyelitis) require longer periods of treatment. Treatment should not be extended beyond 14 days without review (see section 4.4 regarding prolonged therapy).</p><p>&nbsp;</p><p>Children &ge; 40 kg should be treated with the adult formulations of Amoclan BID.</p><p>&nbsp;</p><p><u>Children &lt; 40 kg</u></p><p>Children &nbsp;may &nbsp;be &nbsp;treated &nbsp;with &nbsp;amoxicillin/clavulanic &nbsp;acid &nbsp;tablets, &nbsp;suspensions &nbsp;or &nbsp;paediatric sachets.</p><p>&nbsp;</p><p>Recommended doses:</p><ul><li>25 mg/3.6 mg/kg/day to 45 mg/6.4 mg/kg/day given as two divided doses;&nbsp;</li><li>up to 70 mg/10 mg/kg/day given as two divided doses may be considered for some infections (such as otitis media, sinusitis and lower respiratory tract infections).</li></ul><p>&nbsp;</p><p>No clinical data are available for amoxicillin/clavulanic acid 7:1 formulations regarding doses higher than 45 mg/6.4 mg per kg per day in children under 2 years.</p><p>&nbsp;</p><p>There are no clinical data for amoxicillin/clavulanic acid 7:1 formulations for patients under 2 months of age. Dosing recommendations in this population therefore cannot be made.</p><p>&nbsp;</p><p><u>Elderly</u></p><p>No dose adjustment is considered necessary.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>No dose adjustment is required in patients with creatinine clearance (CrCl) greater than 30 ml/min.</p><p>&nbsp;</p><p>In patients with creatinine clearance less than 30 ml/min, the use of&nbsp; amoxicillin/clavulanic acid presentations with an amoxicillin to clavulanic acid ratio of 7:1 is not recommended, as no recommendations for dose adjustments are available.</p><p>&nbsp;</p><p><u>H</u><u>epatic impairment</u></p><p>Dose with caution and monitor hepatic function at regular intervals (see sections 4.3 and 4.4).</p><p>&nbsp;</p><p><u>M</u><u>ethod of administration</u></p><p>Amoclan BID is for oral use.</p><p>&nbsp;</p><p>Amoclan BID &nbsp;should be administered&nbsp;with a meal&nbsp;to minimise &nbsp;potential gastrointestinal intolerance.</p><p>&nbsp;</p><p>Therapy can be started parenterally according to the SmPC of the IV-formulation and continued with an oral preparation.</p><p>&nbsp;</p><p>Shake to loosen powder, add water as directed, invert and shake.</p><p>&nbsp;</p><p>Shake the bottle before each dose (see section 6.6).</p><p>&nbsp;</p><p>For instructions on reconstitution of the medicinal product before administration, see section 6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients listed in section 6.1.

History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam).

History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid (see section 4.8).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Before initiating therapy with amoxicillin/clavulanic acid, careful enquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins or other beta-lactam agents (see sections 4.3 and 4.8).</p><p>&nbsp;</p><p>Serious and occasionally fatal hypersensitivity reactions (including anaphylactoid and severe cutaneous adverse reactions) have been reported in patients on penicillin therapy. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and in atopic individuals. If an allergic reaction occurs, amoxicillin/clavulanic acid therapy must be discontinued and appropriate alternative therapy instituted.</p><p>&nbsp;</p><p>In the case that an infection is proven to be due to an amoxicillin-susceptible organisms(s) then consideration should be given to switching from amoxicillin/clavulanic acid to amoxicillin in accordance with official guidance.</p><p>&nbsp;</p><p>This presentation of Amoclan BID is not suitable for use when there is a high risk that the presumptive pathogens have resistance to beta-lactam agents that is not mediated by beta- lactamases susceptible to inhibition by clavulanic acid. This presentation should not be used to treat penicillin-resistant S. pneumoniae.</p><p>&nbsp;</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses (see section 4.8).</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid should be avoided if infectious mononucleosis is suspected since the occurrence of a morbilliform rash has been associated with this condition following the use of amoxicillin.</p><p>&nbsp;</p><p>Concomitant use of allopurinol during treatment with amoxicillin can increase the likelihood of allergic skin reactions.</p><p>&nbsp;</p><p>Prolonged use may occasionally result in overgrowth of non-susceptible organisms.</p><p>&nbsp;</p><p>The occurrence at the treatment initiation of a feverish generalised erythema associated with pustula may be a symptom of acute generalised exanthemous pustulosis (AGEP) (see Section 4.8).</p><p>&nbsp;</p><p>This reaction requires amoxicillin/clavulanic acid discontinuation and contraindicates any subsequent administration of amoxicillin.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid should be used with caution in patients with evidence of hepatic impairment (see sections 4.2, 4.3 and 4.8).</p><p>&nbsp;</p><p>Hepatic events have been reported predominantly in males and elderly patients and may be associated with prolonged treatment. These events have been very rarely reported in children. In all populations, signs and symptoms usually occur during or shortly after treatment but in some cases may not become apparent until several weeks after treatment has ceased. These are usually reversible. Hepatic events may be severe and in extremely rare circumstances, deaths have been reported. These have almost always occurred in patients with serious underlying disease or taking concomitant medications known to have the potential for hepatic effects (see section 4.8).</p><p>&nbsp;</p><p>Antibiotic-associated colitis has been reported with nearly all antibacterial agents including amoxicillin and may range in severity from mild to life threatening (see section 4.8). Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of any antibiotics. Should antibiotic-associated colitis occur, amoxicillin/clavulanic acid should immediately be discontinued, a physician be consulted and an appropriate therapy initiated. Anti-peristaltic drugs are contraindicated in this situation.</p><p>&nbsp;</p><p>Periodic assessment of organ system functions, including renal, hepatic and haematopoietic function is advisable during prolonged therapy.</p><p>&nbsp;</p><p>Prolongation of prothrombin time has been reported rarely in patients receiving amoxicillin/clavulanic acid. Appropriate monitoring should be undertaken when anticoagulants are prescribed concomitantly. Adjustments in the dose of oral anticoagulants may be necessary to maintain the desired level of anticoagulation (see sections 4.5 and 4.8).</p><p>&nbsp;</p><p>In patients with renal impairment, the dose should be adjusted according to the degree of impairment (see section 4.2).</p><p>&nbsp;</p><p>In patients with reduced urine output, crystalluria has been observed very rarely, predominantly with parenteral therapy. During the administration of high doses of amoxicillin, it is advisable to maintain adequate fluid intake and urinary output in order to reduce the possibility of amoxicillin crystalluria. In patients with bladder catheters, a regular check of patency should be maintained (see section 4.9).</p><p>&nbsp;</p><p>During treatment with amoxicillin, enzymatic glucose oxidase methods should be used whenever testing for the presence of glucose in urine because false positive results may occur with non- enzymatic methods.</p><p>&nbsp;</p><p>The presence of clavulanic acid in Amoclan BID may cause a non-specific binding of IgG and albumin by red cell membranes leading to a false positive Coombs test.</p><p>&nbsp;</p><p>There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving amoxicillin/clavulanic acid who were subsequently found to be free of Aspergillus infection. Cross-reactions with non-Aspergillus polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia Aspergillus EIA test have been reported. Therefore, positive test results in patients receiving amoxicillin/clavulanic acid should be interpreted cautiously and confirmed by other diagnostic methods.</p><p>&nbsp;</p><p>Amoclan BID 228 mg/5 ml powder for oral suspension contains aspartame, a source of phenylalanine. This medicine should be used with caution in patients with phenylketonuria.</p><p>&nbsp;</p><p>This medicinal product contains golden syrup. Patients with rare hereditary problems of fructose intolerance or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Oral anticoagulants</u></p><p>Oral anticoagulants and penicillin antibiotics have been widely used in practice without reports of interaction. However, in the literature there are cases of increased international normalised ratio in patients maintained on acenocoumarol or warfarin and prescribed a course of amoxicillin. If co-administration is necessary, the prothrombin time or international normalised ratio should be carefully monitored with the addition or withdrawal of amoxicillin. Moreover, adjustments in the dose of oral anticoagulants may be necessary (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><u>M</u><u>ethotrexate</u></p><p>Penicillins may reduce the excretion of methotrexate causing a potential increase in toxicity.</p><p>&nbsp;</p><p><u>P</u><u>robenecid</u></p><p>Concomitant use of probenecid is not recommended. Probenecid decreases the renal tubular secretion of amoxicillin. Concomitant use of probenecid may result in increased and prolonged blood levels of amoxicillin but not of clavulanic acid.</p><p>&nbsp;</p><p><u>My</u><u>c</u><u>o</u><u>ph</u><u>enolate mofetil</u></p><p>In patients receiving mycophenolate mofetil, reduction in pre-dose concentration of the active metabolite mycophenolic acid (MPA) of approximately 50% has been reported following commencement of oral amoxicillin plus clavulanic acid. The change in pre-dose level may not accurately represent changes in overall MPA exposure. Therefore, a change in the dose of mycophenolate mofetil should not normally be necessary in the absence of clinical evidence of graft dysfunction. However, close clinical monitoring should be performed during the combination and shortly after antibiotic treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>P</u><u>regnancy</u></p><p>Pregnancy category B.</p><p>&nbsp;</p><p>Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Limited data on the use of amoxicillin/clavulanic acid during pregnancy in humans do not indicate an increased risk of congenital malformations. In a single study in women with preterm, premature rupture of the foetal membrane it was reported that prophylactic treatment with amoxicillin/clavulanic acid may be associated with an increased risk of necrotising enterocolitis in neonates. Use should be avoided during pregnancy, unless considered essential by the physician.</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>Both substances are excreted into breast milk (nothing is known of the effects of clavulanic acid on the breast-fed infant). Consequently, diarrhoea and fungus infection of the mucous membranes are possible in the breast-fed infant, so that breast-feeding might have to be discontinued. The possibility of sensitisation should be taken into account. Amoxicillin/clavulanic acid should only be used during breast-feeding after benefit/risk assessment by the physician in charge.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. However, undesirable effects may occur (e.g. allergic reactions, dizziness, convulsions), which may influence the ability to drive and use machines (see section 4.8).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse drug reactions (ADRs) are diarrhoea, nausea and vomiting.</p><p>&nbsp;</p><p>The ADRs derived from clinical studies and post-marketing surveillance with amoxicillin/clavulanic acid, sorted by MedDRA System Organ Class are listed below.</p><p>&nbsp;</p><p>The following terminologies have been used in order to classify the occurrence of undesirable effects.</p><p>Very common (&ge;1/10)</p><p>Common (&ge;1/100 to &lt;1/10)</p><p>Uncommon (&ge;1/1,000 to &lt;1/100)</p><p>Rare (&ge;1/10,000 to &lt;1/1,000)</p><p>Very rare (&lt;1/10,000)</p><p>Not known (cannot be estimated from the available data)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="2"><p><strong><u>I</u></strong><strong><u>n</u></strong><strong><u>fections and infestations</u></strong></p></td></tr><tr><td><p>Mucocutaneous candidosis</p></td><td><p>Common</p></td></tr><tr><td><p>Overgrowth of non-susceptible organisms</p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>Bl</u></strong><strong><u>oo</u></strong><strong><u>d and lymphatic system disorders</u></strong></p></td></tr><tr><td><p>Reversible leucopenia (including neutropenia)</p></td><td><p>Rare</p></td></tr><tr><td><p>Thrombocytopenia</p></td><td><p>Rare</p></td></tr><tr><td><p>Reversible agranulocytosis</p></td><td><p>Not known</p></td></tr><tr><td><p>Haemolytic anaemia</p></td><td><p>Not known</p></td></tr><tr><td><p>Prolongation of bleeding time and prothrombin time<sup>1</sup></p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>I</u></strong><strong><u>mmune system disorders</u></strong><sup><strong>10</strong></sup></p></td></tr><tr><td><p>Angioneurotic oedema</p></td><td><p>Not known</p></td></tr><tr><td><p>Anaphylaxis</p></td><td><p>Not known</p></td></tr><tr><td><p>Serum sickness-like syndrome</p></td><td><p>Not known</p></td></tr><tr><td><p>Hypersensitivity vasculitis</p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>N</u></strong><strong><u>e</u></strong><strong><u>r</u></strong><strong><u>v</u></strong><strong><u>ou</u></strong><strong><u>s system disorders</u></strong></p></td></tr><tr><td><p>Dizziness</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Headache</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Reversible hyperactivity</p></td><td><p>Not known</p></td></tr><tr><td><p>Convulsions<sup>2</sup></p></td><td><p>Not known</p></td></tr><tr><td><p>Aseptic meningitis</p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>G</u></strong><strong><u>a</u></strong><strong><u>strointestinal disorders</u></strong></p></td></tr><tr><td><p>Diarrhoea</p></td><td><p>Common</p></td></tr><tr><td><p>Nausea<sup>3</sup></p></td><td><p>Common</p></td></tr><tr><td><p>Vomiting</p></td><td><p>Common</p></td></tr><tr><td><p>Indigestion</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Antibiotic-associated colitis<sup>4</sup></p></td><td><p>Not known</p></td></tr><tr><td><p>Black hairy tongue</p></td><td><p>Not known</p></td></tr><tr><td><p>Tooth discolouration<sup>11</sup></p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>Hepatobiliary disorders</u></strong></p></td></tr><tr><td><p>Rises in AST and/or ALT<sup>5</sup></p></td><td><p>Uncommon</p></td></tr><tr><td><p>Hepatitis<sup>6</sup></p></td><td><p>Not known</p></td></tr><tr><td><p>Cholestatic jaundice<sup>6</sup></p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>S</u></strong><strong><u>kin and subcutaneous tissue disorders </u></strong><sup><strong><u>7</u></strong></sup></p></td></tr><tr><td><p>Skin rash</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Pruritus</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Urticaria</p></td><td><p>Uncommon</p></td></tr><tr><td><p>Erythema multiforme</p></td><td><p>Rare</p></td></tr><tr><td><p>Stevens-Johnson syndrome</p></td><td><p>Not known</p></td></tr><tr><td><p>Toxic epidermal necrolysis</p></td><td><p>Not known</p></td></tr><tr><td><p>Bullous exfoliative-dermatitis</p></td><td><p>Not known</p></td></tr><tr><td><p>Acute&nbsp;generalised&nbsp;exanthemous&nbsp;pustulosis (AGEP)<sup>9</sup></p></td><td><p>Not known</p></td></tr><tr><td><p>&nbsp;Drug reaction with eosinophilia and systemic symptoms (DRESS)</p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><strong><u>Renal and urinary disorders</u></strong></p></td></tr><tr><td><p>&nbsp;Interstitial nephritis</p></td><td><p>Not known</p></td></tr><tr><td><p>&nbsp;Crystalluria<sup>8</sup></p></td><td><p>Not known</p></td></tr><tr><td colspan="2"><p><sup>1</sup> See section 4.4</p><p><sup>2 </sup>See section 4.4</p><p><sup>3 </sup>Nausea is more often associated with higher oral doses. If gastrointestinal reactions are evident, they may be reduced by taking amoxicillin/clavulanic acid with a meal.</p><p><sup>4 </sup>Including pseudomembranous colitis and haemorrhagic colitis (see section 4.4)</p><p><sup>5 </sup>A moderate rise in AST and/or ALT has been noted in patients treated with beta-lactam class antibiotics, but the significance of these findings is unknown.</p><p><sup>6</sup> These events have been noted with other penicillins and cephalosporins (see section 4.4).</p><p><sup>7</sup> If any hypersensitivity dermatitis reaction occurs, treatment should be discontinued (see section 4.4).</p><p><sup>8</sup> See section 4.9</p><p><sup>9</sup> See section 4.4</p><p><sup>10</sup> See sections 4.3 and 4.4</p><p><sup>11</sup> Superficial tooth discolouration has been reported very rarely in children. Good oral hygiene may help to prevent tooth discolouration as it can usually be removed by brushing.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong><u>Reporting of suspected adverse events:</u></strong></p><p>Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting systems applied at their countries.</p><ul><li>Saudi Arabia</li></ul><p>The National Pharmacovigilance and Drug Safety Center (NPC)</p><p>Fax: +966-11-2057662</p><p>Toll free: 800-249-0000</p><p>Phone No.: +966-11-2038222, Exts: 2317-2340-2356.</p><p>e-mail: &nbsp;npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p><p>&nbsp;</p><ul><li>Other GCC States:</li></ul><p>Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and signs of overdose</u></p><p>Gastrointestinal symptoms and disturbance of the fluid and electrolyte balances may be evident. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed (see section 4.4).</p><p>&nbsp;</p><p>Convulsions may occur in patients with impaired renal function or in those receiving high doses.</p><p>&nbsp;</p><p>Amoxicillin &nbsp;has &nbsp;been &nbsp;reported &nbsp;to &nbsp;precipitate &nbsp;in &nbsp;bladder &nbsp;catheters, &nbsp;predominantly &nbsp;after intravenous administration of large doses. A regular check of patency should be maintained (see section 4.4)</p><p>&nbsp;</p><p><u>Treatment of intoxication</u></p><p>Gastrointestinal symptoms may be treated symptomatically, with attention to the water/electrolyte balance.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid can be removed from the circulation by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Combinations of penicillins, incl. beta-lactamase inhibitors; ATC code: J01CR02.</p><p>&nbsp;</p><p><u>Mo</u><u>d</u><u>e of action</u></p><p>Amoxicillin is a semisynthetic penicillin (beta-lactam antibiotic) that inhibits one or more enzymes (often referred to as penicillin-binding proteins, PBPs) in the biosynthetic pathway of bacterial peptidoglycan, which is an integral structural component of the bacterial cell wall. Inhibition of peptidoglycan synthesis leads to weakening of the cell wall, which is usually followed by cell lysis and death.</p><p>&nbsp;</p><p>Amoxicillin is susceptible to degradation by beta-lactamases produced by resistant bacteria and therefore the spectrum of activity of amoxicillin alone does not include organisms which produce these enzymes.</p><p>&nbsp;</p><p>Clavulanic acid is a beta-lactam structurally related to penicillins. It inactivates some beta- lactamase enzymes thereby preventing inactivation of amoxicillin. Clavulanic acid alone does not exert a clinically useful antibacterial effect.</p><p>&nbsp;</p><p><u>P</u><u>h</u><u>armacokinetic/pharmacodynamic relationship</u></p><p>The time above the minimum inhibitory concentration (T&gt;MIC) is considered to be the major determinant of efficacy for amoxicillin.</p><p>&nbsp;</p><p><u>M</u><u>echanisms of resistance</u></p><p>The two main mechanisms of resistance to amoxicillin/clavulanic acid are:</p><ul><li>Inactivation by those bacterial beta-lactamases that are not themselves inhibited by clavulanic acid, including class B, C and D.</li><li>Alteration of PBPs, which reduce the affinity of the antibacterial agent for the target.</li></ul><p>&nbsp;</p><p>Impermeability of bacteria or efflux pump mechanisms may cause or contribute to bacterial resistance, particularly in Gram-negative bacteria.</p><p>&nbsp;</p><p><u>Breakpoints</u></p><p>MIC &nbsp;breakpoints for amoxicillin/clavulanic acid &nbsp;are those of the European Committee on Antimicrobial Susceptibility Testing (EUCAST)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Organism</p></td><td colspan="3"><p>Susceptibility Breakpoints (&mu;g/ml)</p></td></tr><tr><td><p>&nbsp;</p></td><td><p>Susceptible</p></td><td><p>Intermediate</p></td><td><p>Resistant</p></td></tr><tr><td><p><em>Ha</em><em>emophilus influenzae</em><sup><strong>1</strong></sup></p></td><td><p>&le; 1</p></td><td><p>-</p></td><td><p>&gt; 1</p></td></tr><tr><td><p><em>M</em><em>oraxella catarrhalis</em><sup><strong>1</strong></sup></p></td><td><p>&le; 1</p></td><td><p>-</p></td><td><p>&gt; 1</p></td></tr><tr><td><p><em>S</em><em>taphylococcus aureus </em><sup><strong>2</strong></sup></p></td><td><p>&le; 2</p></td><td><p>-</p></td><td><p>&gt; 2</p></td></tr><tr><td><p>Coagulase-negative staphylococci <sup><strong>2</strong></sup></p></td><td><p>&le; 0.25</p></td><td><p>&nbsp;</p></td><td><p>&gt; 0.25</p></td></tr><tr><td><p><em>Enterococcus</em><sup><strong>1</strong></sup></p></td><td><p>&le; 4</p></td><td><p>8</p></td><td><p>&gt; 8</p></td></tr><tr><td><p><em>S</em><em>treptococcus A, B, C, G</em><sup><strong>5</strong></sup></p></td><td><p>&le; 0.25</p></td><td><p>-</p></td><td><p>&gt; 0.25</p></td></tr><tr><td><p><em>S</em><em>treptococcus pneumoniae</em><sup><strong>3</strong></sup></p></td><td><p>&le; 0.5</p></td><td><p>1-2</p></td><td><p>&gt; 2</p></td></tr><tr><td><p>Enterobacteriaceae<sup><strong>1</strong><strong>,4</strong></sup></p></td><td><p>-</p></td><td><p>-</p></td><td><p>&gt; 8</p></td></tr><tr><td><p>Gram-negative Anaerobes<sup><strong>1</strong></sup></p></td><td><p>&le; 4</p></td><td><p>8</p></td><td><p>&gt; 8</p></td></tr><tr><td><p>Gram-positive Anaerobes<sup><strong>1</strong></sup></p></td><td><p>&le; 4</p></td><td><p>8</p></td><td><p>&gt; 8</p></td></tr><tr><td><p>Non-species related breakpoints<sup><strong>1</strong></sup></p></td><td><p>&le; 2</p></td><td><p>4-8</p></td><td><p>&gt; 8</p></td></tr><tr><td colspan="4"><p><sup>1 </sup>&nbsp;The reported values are for Amoxicillin concentrations. For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/l.</p><p><sup>2</sup> The reported values are oxacillin concentrations.</p><p><sup>3</sup> Breakpoint values in the table are based on ampicillin breakpoints.</p><p><sup>4</sup> The resistant breakpoint of R&gt;8 mg/l ensures that all isolates with resistance mechanisms are reported resistant.</p><p><sup>5</sup> Breakpoint values in the table are based on benzylpenicillin breakpoints.</p></td></tr></tbody></table><p>&nbsp;</p><p>The prevalence of resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td><p><u>Commonly susceptible species</u></p></td></tr><tr><td><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecalis</em></p><p><em>Gardnerella vaginalis</em></p><p><em>S</em><em>taphylococcus aureus (</em>methicillin-susceptible) &pound;</p><p><em>Coagulase-negative staphylococci (methicillin-susceptible) </em></p><p><em>Streptococcus agalactiae</em></p><p><em>S</em><em>treptococcus pneumoniae</em><sup>1</sup></p><p><em>S</em><em>treptococcus pyogenes </em>and other beta-haemolytic streptococci</p><p><em>S</em><em>treptococcus viridans </em>group</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Capnocytophaga </em>spp.</p><p><em>Eikenella corrodens </em></p><p><em>Haemophilus influenzae</em><sup>2</sup></p><p><em>M</em><em>oraxella catarrhalis </em></p><p><em>Pasteurella multocida </em></p><p><u>Anaerobic micro-organisms</u></p><p><em>Bacteroides fragilis </em></p><p><em>Fusobacterium nucleatum </em></p><p><em>Prevotella </em>spp.</p></td></tr><tr><td><p><u>Species for which acquired resistance may be a problem</u></p></td></tr><tr><td><p><u>Aerobic Gram-positive micro-organisms</u></p><p><em>Enterococcus faecium </em>$</p><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Escherichia coli</em></p><p><em>Klebsiella oxytoca </em></p><p><em>Klebsiella pneumoniae </em></p><p><em>Proteus mirabilis</em></p><p><em>Pr</em><em>oteus vulgaris</em></p></td></tr><tr><td><p><u>Inherently resistant organisms</u></p></td></tr><tr><td><p><u>Aerobic Gram-negative micro-organisms</u></p><p><em>Acinetobacter </em>sp.</p><p><em>Citrobacter freundii </em></p><p><em>Enterobacter </em>sp.</p><p><em>Legionella pneumophila </em></p><p><em>Morganella morganii</em></p><p><em>Providencia </em>spp.</p><p><em>Pseudomonas </em>sp.</p><p><em>Serratia </em>sp.</p><p><em>S</em><em>tenotrophomonas maltophilia </em></p><p><u>Other micro-organisms</u></p><p><em>Chlamydophila pneumoniae </em></p><p><em>Chlamydophila psittaci</em></p><p><em>Coxiella burnetti</em></p><p><em>M</em><em>ycoplasma pneumoniae</em></p></td></tr><tr><td><p>$ Natural intermediate susceptibility in the absence of acquired mechanism of resistance.</p><p>&pound; All methicillin-resistant staphylococci are resistant to amoxicillin/clavulanic acid.</p><p><sup>1 </sup>&nbsp;<em>Streptococcus &nbsp;pneumoniae </em>that are resistant to penicillin&nbsp;should not be &nbsp;treated with this&nbsp;presentation&nbsp;of amoxicillin/clavulanic acid (see sections 4.2 and 4.4).</p><p><sup>2</sup> Strains with decreased susceptibility have been reported in some countries in the EU with a frequency higher than 10%.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Amoxicillin and clavulanic acid, are fully dissociated in aqueous solution at physiological pH. Both components are rapidly and well absorbed by the oral route of administration. Following oral administration, amoxicillin and clavulanic acid are approximately 70% bioavailable. The plasma profiles of both components are similar and the time to peak plasma concentration (T<sub>max</sub>) in each case is approximately one hour.</p><p>&nbsp;</p><p>The pharmacokinetic results for a study, in which amoxicillin/clavulanic acid (875 mg/125 mg tablets given twice daily) was administered in the fasting state to groups of healthy volunteers are presented below.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td colspan="6"><p>Mean (&plusmn; SD) pharmacokinetic parameters</p></td></tr><tr><td rowspan="2"><p>Active substance(s) administered</p></td><td><p>Dose</p></td><td><p>C<sub>max</sub></p></td><td><p>T<sub>max</sub> *</p></td><td><p>AUC <sub>(0-24h)</sub></p></td><td><p>T <sub>1/2</sub></p></td></tr><tr><td><p>(mg)</p></td><td><p>(&mu;g/ml)</p></td><td><p>(h)</p></td><td><p>(&mu;g.h/ml)</p></td><td><p>(h)</p></td></tr><tr><td colspan="6"><p>Amoxicillin</p></td></tr><tr><td><p>AMX/CA</p><p>875 mg/125 mg</p></td><td><p>875</p></td><td><p>11.64 &plusmn; 2.78</p></td><td><p>1.50 (1.0-2.5)</p></td><td><p>53.52 &plusmn; 12.31</p></td><td><p>1.19 &plusmn; 0.21</p></td></tr><tr><td colspan="6"><p>Clavulanic acid</p></td></tr><tr><td><p>AMX/CA</p><p>875 mg/125 mg</p></td><td><p>125</p></td><td><p>2.18 &plusmn; 0.99</p></td><td><p>1.25 (1.0-2.0)</p></td><td><p>10.16 &plusmn; 3.04</p></td><td><p>0.96 &plusmn; 0.12</p></td></tr><tr><td colspan="6"><p>AMX &ndash; amoxicillin, CA &ndash; clavulanic acid</p><p>* Median (range)</p></td></tr></tbody></table><p>&nbsp;</p><p>Amoxicillin and clavulanic acid serum concentrations achieved with amoxicillin/clavulanic acid are similar to those produced by the oral administration of equivalent doses of amoxicillin or clavulanic acid alone.</p><p>&nbsp;</p><p><u>D</u><u>istribution</u></p><p>About 25% of total plasma clavulanic acid and 18% of total plasma amoxicillin is bound to protein. The apparent volume of distribution is around 0.3-0.4 l/kg for amoxicillin and around 0.2 l/kg for clavulanic acid.</p><p>&nbsp;</p><p>Following intravenous administration, both amoxicillin and clavulanic acid have been found in gall bladder, abdominal tissue, skin, fat, muscle tissues, synovial and peritoneal fluids, bile and pus. Amoxicillin does not adequately distribute into the cerebrospinal fluid.</p><p>&nbsp;</p><p>From animal studies there is no evidence for significant tissue retention of drug-derived material for either component. Amoxicillin, like most penicillins, can be detected in breast milk. Trace quantities of clavulanic acid can also be detected in breast milk (see section 4.6).</p><p>Both amoxicillin and clavulanic acid have been shown to cross the placental barrier (see section 4.6).</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Amoxicillin is partly excreted in the urine as the inactive penicilloic acid in quantities equivalent to up to 10 to 25% of the initial dose. Clavulanic acid is extensively metabolized in man and eliminated in urine and faeces and as carbon dioxide in expired air.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>The major route of elimination for amoxicillin is via the kidney, whereas for clavulanic acid it is by both renal and non-renal mechanisms.</p><p>&nbsp;</p><p>Amoxicillin/clavulanic acid has a mean elimination half-life of approximately one hour and a mean total clearance of approximately 25 l/h in healthy subjects. Approximately 60 to 70% of the amoxicillin and approximately 40 to 65% of the clavulanic acid are excreted unchanged in urine during the first 6 h after administration of single amoxicillin/clavulanic acid 250 mg/125 mg or 500 mg/125 mg tablets. Various studies have found the urinary excretion to be 50-85% for amoxicillin and between 27-60% for clavulanic acid over a 24 hour period. In the case of clavulanic acid, the largest amount of drug is excreted during the first 2 hours after administration.</p><p>&nbsp;</p><p>Concomitant use of probenecid delays amoxicillin excretion but does not delay renal excretion of clavulanic acid (see section 4.5).</p><p>&nbsp;</p><p><u>Age</u></p><p>The elimination half-life of amoxicillin is similar for children aged around 3 months to 2 years and older children and adults. For very young children (including preterm newborns) in the first week of life the interval of administration should not exceed twice daily administration due to immaturity of the renal pathway of elimination. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p><p>&nbsp;</p><p><u>Gender</u></p><p>Following oral administration of amoxicillin/clavulanic acid to healthy males and female subjects, gender has no significant impact on the pharmacokinetics of either amoxicillin or clavulanic acid.</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>The total serum clearance of amoxicillin/clavulanic acid decreases proportionately with decreasing renal function. The reduction in drug clearance is more pronounced for amoxicillin than for clavulanic acid, as a higher proportion of amoxicillin is excreted via the renal route. Doses in renal impairment must therefore prevent undue accumulation of amoxicillin while maintaining adequate levels of clavulanic acid (see section 4.2).</p><p>&nbsp;</p><p><u>H</u><u>epatic impairment</u></p><p>Hepatically impaired patients should be dosed with caution and hepatic function monitored at regular intervals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Nonclinical data reveal no special hazard for humans based on studies of safety pharmacology, genotoxicity and toxicity to reproduction.</p><p>&nbsp;</p><p>Repeat dose toxicity studies performed in dogs with amoxicillin/clavulanic acid demonstrate gastric irritancy and vomiting, and discoloured tongue.</p><p>&nbsp;</p><p>Carcinogenicity studies have not been conducted with amoxicillin/clavulanic acid.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>- Xanthan gum<br />- Aspartame<br />- Colloidal silicon dioxide<br />- Succinic acid<br />- Hydroxylpropyl methyl cellulose<br />- Orange flavor<br />- Golden syrup<br />- Silicon dioxide</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dry powder: 24 months.

Liquid suspension: Once made up, the suspension should be used within 7 days.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Dry Powder:</strong><br />Store below 25&deg;C.</p><p><br />Store in the original carton in order to protect from moisture.</p><p><br /><strong>Liquid suspension:</strong><br />Store in a refrigerator (2-8&deg;C).</p><p>&nbsp;</p><p>Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminum-sealed type (III) amber glass bottles with a mark at 100 ml with child resistant caps with a plastic dosing syringe calibrated in milliliters (ml).</p><p><br />Pack size: 1 bottle (35 ml or 70 ml).</p><p><br />Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bottles may be supplied with a ring-seal on the neck of the cap or with a removable foil-backed seal on the mouth of the bottle.</p><p><br /><em>Instructions for reconstitution</em><br />Remove cap and check aluminum-backed bottle seal is intact before using.</p><p><br />Invert bottle and shake powder loose. Add cooled boiled water up to the mark in two portions shaking after each addition until a homogeneous suspension is achieved. When first reconstituted allow to stand for five minutes to ensure full dispersion.</p><p><br />Shake the bottle well before each dose.</p><p><br />Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hikma Pharmaceuticals
Bayader Wadi El Seer
Industrial Area
P.O Box 182400
Amman 11118, Jordan
Tel: (962-6)5802900
Fax: (962-6)5817102
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08 November 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>